tiprankstipranks
Trending News
More News >
Sinopharm Group Co Class H (HK:1099)
:1099
Hong Kong Market

Sinopharm Group Co (1099) Stock Forecast & Price Target

Compare
7 Followers
See the Price Targets and Ratings of:

1099 Financial Forecast

1099 Earnings Forecast

Next quarter’s earnings estimate for 1099 is HK$1.06 with a range of HK$1.06 to HK$1.06. The previous quarter’s EPS was HK$0.51. 1099 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.12% of the time in the same period. In the last calendar year 1099 has Preformed in-line its overall industry.
Next quarter’s earnings estimate for 1099 is HK$1.06 with a range of HK$1.06 to HK$1.06. The previous quarter’s EPS was HK$0.51. 1099 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.12% of the time in the same period. In the last calendar year 1099 has Preformed in-line its overall industry.

1099 Sales Forecast

Next quarter’s sales forecast for 1099 is HK$318.18B with a range of HK$318.18B to HK$318.18B. The previous quarter’s sales results were ―. 1099 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year 1099 has Outperformed its overall industry.
Next quarter’s sales forecast for 1099 is HK$318.18B with a range of HK$318.18B to HK$318.18B. The previous quarter’s sales results were ―. 1099 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year 1099 has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on HK:1099
TipRanks AITipRanks
Not Ranked
TipRanks
HK$21.5
Buy
16.22%
Upside
Reiterated
06/10/25
Sinopharm Group Co's stock is well-positioned with strong technical indicators and attractive valuation metrics leading the positive assessment. Despite stable financial performance, the pressure on profit margins and variability in free cash flow present areas for improvement.
Nomura
HK$25.09HK$23.4
Buy
26.49%
Upside
Reiterated
03/25/25
Sinopharm Group Co Ltd. (1099:HK) (SHTDF) PT Lowered to HK$23.40 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang lowered the price target on Sinopharm Group Co Ltd. (1099:HK) (OTC: SHTDF) to HK$23.40 (from HK$25.09) while maintaining a Buy rating.
DBS
HK$15HK$25
Buy
35.14%
Upside
Upgraded
12/12/24
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS) and Sinopharm Group Co (Other OTC: SHTDF)
Jefferies Analyst forecast on HK:1099
Unknown AnalystJefferies
Not Ranked
Jefferies
HK$21.4
Hold
15.68%
Upside
Downgraded
10/25/24
Morgan Stanley Analyst forecast on HK:1099
Laurence TamMorgan Stanley
Morgan Stanley
HK$27HK$25
Buy
35.14%
Upside
Reiterated
08/26/24
Sinopharm Group Co Ltd. (1099:HK) (SHTDF) PT Lowered to HK$25 at Morgan StanleyMorgan Stanley analyst Laurence Tam lowered the price target on Sinopharm Group Co Ltd. (1099:HK) (OTC: SHTDF) to HK$25.00 (from HK$27.00) while maintaining a Overweight rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on HK:1099
TipRanks AITipRanks
Not Ranked
TipRanks
HK$21.5
Buy
16.22%
Upside
Reiterated
06/10/25
Sinopharm Group Co's stock is well-positioned with strong technical indicators and attractive valuation metrics leading the positive assessment. Despite stable financial performance, the pressure on profit margins and variability in free cash flow present areas for improvement.
Nomura
HK$25.09HK$23.4
Buy
26.49%
Upside
Reiterated
03/25/25
Sinopharm Group Co Ltd. (1099:HK) (SHTDF) PT Lowered to HK$23.40 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang lowered the price target on Sinopharm Group Co Ltd. (1099:HK) (OTC: SHTDF) to HK$23.40 (from HK$25.09) while maintaining a Buy rating.
DBS
HK$15HK$25
Buy
35.14%
Upside
Upgraded
12/12/24
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS) and Sinopharm Group Co (Other OTC: SHTDF)
Jefferies Analyst forecast on HK:1099
Unknown AnalystJefferies
Not Ranked
Jefferies
HK$21.4
Hold
15.68%
Upside
Downgraded
10/25/24
Morgan Stanley Analyst forecast on HK:1099
Laurence TamMorgan Stanley
Morgan Stanley
HK$27HK$25
Buy
35.14%
Upside
Reiterated
08/26/24
Sinopharm Group Co Ltd. (1099:HK) (SHTDF) PT Lowered to HK$25 at Morgan StanleyMorgan Stanley analyst Laurence Tam lowered the price target on Sinopharm Group Co Ltd. (1099:HK) (OTC: SHTDF) to HK$25.00 (from HK$27.00) while maintaining a Overweight rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sinopharm Group Co

1 Month
xxx
Success Rate
2/7 ratings generated profit
29%
Average Return
-1.46%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 28.57% of your transactions generating a profit, with an average return of -1.46% per trade.
3 Months
xxx
Success Rate
3/7 ratings generated profit
43%
Average Return
-4.67%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -4.67% per trade.
1 Year
Success Rate
0/7 ratings generated profit
0%
Average Return
-11.97%
reiterated a buy rating 3 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -11.97% per trade.
2 Years
xxx
Success Rate
0/7 ratings generated profit
0%
Average Return
-13.93%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -13.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1099 Analyst Recommendation Trends

Rating
Aug 24
Oct 24
Dec 24
Feb 25
Mar 25
Strong Buy
7
4
4
3
3
Buy
0
0
0
0
0
Hold
1
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
5
5
4
3
In the current month, 1099 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1099 average Analyst price target in the past 3 months is 23.39.
Each month's total comprises the sum of three months' worth of ratings.

1099 Stock Forecast FAQ

What is HK:1099’s average 12-month price target, according to analysts?
Based on analyst ratings, Sinopharm Group Co Class H’s 12-month average price target is 23.39.
    What is HK:1099’s upside potential, based on the analysts’ average price target?
    Sinopharm Group Co Class H has 26.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sinopharm Group Co Class H a Buy, Sell or Hold?
          Sinopharm Group Co Class H has a consensus rating of Moderate Buy, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Sinopharm Group Co Class H’s share price target?
            The average share price target for Sinopharm Group Co Class H is 23.39. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$23.40 ,and the lowest forecast is HK$23.40. The average share price target represents 26.45% Increase from the current price of HK$18.5.
              What do analysts say about Sinopharm Group Co Class H?
              Sinopharm Group Co Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of Sinopharm Group Co Class H?
                To buy shares of HK:1099, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis